Nanjing, China
Nanjing, China

Time filter

Source Type

Cui Q.-L.,Zhengzhou University | Cui Q.-L.,Zhejiang Chinese Medical University | Shao M.,No81 Hospital Of Pla | Shao M.,Zhejiang Chinese Medical University | Shu Q.-J.,Zhejiang Chinese Medical University
Zhongguo Zhongyao Zazhi | Year: 2013

Objective: To study the effect of aqueous extract of Taxus chinensis var. mairei (AETC) on the growth of A549 lung cancer xenografts in nude mice and its mechanism. Method: The A549 lung cancer xenograft model was established, and then randomly divided into the control group, and low, middle and high dose AETC experiment groups. After 24 hours, they were orally administered with normal saline and drugs of the same volume for seven weeks. The length and width of the xenografts were measured every three days, and the xenograft growth curve was drawn. The nude mice were sacrificed after the administration for seven weeks, and their xenografts were collected to cultivate the anti-tumor rate. Real-time PCR and Western-blot were adopted to detect mRNA and protein levels. Result: All of AETC experiment groups showed a significant anti-tumor effect (P<0.05). Compared with the control group, each experimental group showed notable reduction in EGFR and Survivin mRNA in xenograft tissues (P<0.05), with no significant change in VEGF mRNA level. The analysis on gray value ratio showed that EGFR mRNA were down-regulated (P<0.05) in xenograft tissues in all experimental groups, but with no statistical significance in difference, and Survivin and p-EGFR were significantly down-regulated. Conclusion: AETC has not significant effect on angiogenesis, but may have the inhibitory effect on xenograft growth by inhibiting Survivin protein and EGFR phosphorylation.


Wei W.,No81 Hospital Of Pla
Nan fang yi ke da xue xue bao = Journal of Southern Medical University | Year: 2010

To evaluate the efficacy and drug resistance of azithromycin administered via continuous infusion versus intermittent administration in rats with Mycoplasma pneumonia-induced pneumonia. Pneumonia was induced in rats by intranasal administration of mycoplasma suspension. The rats with established pneumonia were randomly divided into continuous and intermittent infusion groups with intraperitoneal azithromycin injection on a daily basis for 6 consecutive days, or for 3 consecutive days followed by a 3-day rest (which was repeated twice), respectively. The bronchoalveolar lavage (BAL) and venous blood were collected before and at 3, 6, 9, and 12 days during or after the treatments for MIC test. The rats were killed for lung pathological examination, and the plasma samples were obtained for drug assays by HPLC. Pathological examination of the lungs demonstrated better improvement in the intermittent group than in continuous group. At 12 days of the treatment, the MIC value was higher in the continuous group than in the intermittent group. Intermittent azithromycin administration produces better therapeutic effect against Mycoplasma pneumonia than continuous drug delivery in rats with less likeliness of inducing drug resistance.


Zheng J.,No81 Hospital Of Pla | Jiang L.,No81 Hospital Of Pla | Yao L.,No81 Hospital Of Pla | Ai Y.,No81 Hospital Of Pla | And 8 more authors.
Chinese Journal of Cancer Biotherapy | Year: 2015

Objective:To evaluate the safety and efficacy of combination therapy with dendritic cells (DCs) and cytokine-induced killer (CIK) cells in the treatment of advanced colorectal cancer (CRC). Methods: Peripheral blood mononuclear cells (PBMCs) were collected from 142 patients with stage Ⅲ~Ⅳ CRC who were admitted to the Tumor Biotherapy Center of the No. 81 Hospital of PLA in Nanjing from August, 2011 to December, 2014. The cells were cultured ex vivo to generate DC and CIK cells. After sensitized with cell lysates from colon cancer cells Colo-320 or rectal cancer cells HCT-116, the DCs were transfused to CRC patients after combined with the CIK cells. T-lymphocyte subsets, serum CEA level, and clinical features were evaluated before and after the combined DC and CIK treatment. Results: Following the combined DC and CIK immunotherapy in patients with advanced CRC for 40 months, the overall response rate was 16.2%, the disease control rate was 60.0%, one-year overall survival rate was 47%, and both two-year and three-year overall survival rate was maintained at 31%. No significant alterations in T-lymphocyte subsets, CD4+/CD8+ ratio, and CEA level were found in these patients after the combination therapy. Single-factor analysis indicated that tumor stage (P=0.015), the frequency of immunotherapy (P=0.037), and CEA value (P=0.037) affected significantly the survival period of these CRC patients. Multivariate Cox model indicated that frequency of the combined DC and CIK immunotherapy (P=0.024) and age (P=0.015) associated significantly with the risk of cancer-related death in these CRC patients. Conclusion: The combined autologous DC/CIK immunotherapy is a safe and feasible therapeutic approach and it may improve the long-term survival rate in patients with stage Ⅲ~Ⅳ CRC. © 2015, Editorial office of Chinese Journal of Cancer Biotherapy. All rights reserved.


PubMed | No81 Hospital Of Pla
Type: Journal Article | Journal: Nan fang yi ke da xue xue bao = Journal of Southern Medical University | Year: 2010

To evaluate the efficacy and drug resistance of azithromycin administered via continuous infusion versus intermittent administration in rats with Mycoplasma pneumonia-induced pneumonia.Pneumonia was induced in rats by intranasal administration of mycoplasma suspension. The rats with established pneumonia were randomly divided into continuous and intermittent infusion groups with intraperitoneal azithromycin injection on a daily basis for 6 consecutive days, or for 3 consecutive days followed by a 3-day rest (which was repeated twice), respectively. The bronchoalveolar lavage (BAL) and venous blood were collected before and at 3, 6, 9, and 12 days during or after the treatments for MIC test. The rats were killed for lung pathological examination, and the plasma samples were obtained for drug assays by HPLC.Pathological examination of the lungs demonstrated better improvement in the intermittent group than in continuous group. At 12 days of the treatment, the MIC value was higher in the continuous group than in the intermittent group.Intermittent azithromycin administration produces better therapeutic effect against Mycoplasma pneumonia than continuous drug delivery in rats with less likeliness of inducing drug resistance.


Li H.,No81 Hospital Of Pla | Qin S.-K.,No81 Hospital Of Pla | Liu X.-F.,No81 Hospital Of Pla | Gong X.-L.,No81 Hospital Of Pla | And 4 more authors.
Chinese Journal of Cancer Prevention and Treatment | Year: 2015

OBJECTIVE: To observe the efficacy and safety of gemcitabine based chemotherapy combined with endostar treatment for patients with advancerd biliary tract carcinoma, and explore the role of endostar in BTC. METHODS: One hundred and nine patients from 1st Jan, 2005 to 1st Apr. 2015, confirmed with pathologic and imaging examination as stage IVB biliary tract carcinoma were reviewed. Totally 25 cases received GP(n=1)/GEMOX(n=22)/GX(n=2)+endostar regimens and 84 cases were applied with GP(n=9)/GEMOX(n=40)/GX(n=35)regimens alone. GP regimen was given as follows: gemcitabine 1 000 mg/m2 iv, d1, d8; cisplatin 20 mg iv, d2-d6. GEMOX regimen was given as follows: gemcitabine 1 000 mg/m2 iv, d1, d8; oxaliplatin 100 mg/m2 iv, d2. GX regimen was given as follows: gemcitabine 1 000 mg/m2 iv, d1, d8; capecitabine 1 000 mg/m2, bid, d1-d14, 21 days was a cycle. Endostar was given 15 mg iv d1-d14, also 21 days was a cycle. The efficacy was evaluated strictly after 2 cycles according to RECIST 1.0 criteria, safety was evaluated after 1 cycle according to NCI CTC 3.0 version criteria, drawing survival curve with Kaplan Meier(Log-Rank test compared two groups). RESULTS: In GP/GEMOX/GX +endostar group, 1 was in CR, 8 in PR, 12 in SD and 4 in PD.The response rate(RR) was 36.0%, disease control rate(DCR) was 84.0%, median progression free survival (PFS) was 5.8 months and median overall survival(OS) was 12.3 months, the quality of life(QOL) improved and stable rate was 88.0%.In GP/GEMOX/GX group, 1 was in CR, 10 in PR, 42 in SD, and 31 in PD. The response rate resonse rate(RR) was 13.1%, disease control rate(DCR) was 63.1%. Median progression-free survival(PFS) was 3.8 months and median overall survival(OS) was 8.0 months. The quality of life(QOL) improved and stable rate was 80.9%.There was statistical difference both in RR, DCR, PFS and OS between the two groups(P<0.05). The most common toxicities in the two groups were myelosuppression, other main toxicities included nausea, vomiting, peripheral neuritis, rash, fever, hand and foot syndrome and etc, mainly in grade 1-2, and there were no significant difference between the two groups(P>0.05). In GP/GEMOX/GX+endostar group, only 2 cases of non-specific T wave changed. One case of auricular flutter and 1 with mild hypertension. CONCLUSION: It is suggested that gemcitabine based chemotherapy combined with endostar has good efficacy in advanced BTC, and prolong PFS and OS, and the toxicities are well-tolerated, which deserves clinical use and further observation. © 2015, Editorial Board of Chinese Journal of Cancer Prevention and Treatment. All right reserved.

Loading No81 Hospital Of Pla collaborators
Loading No81 Hospital Of Pla collaborators